Labmanager Logo
Bacteria Lactobacillus in human intestine

iStock, nopparit

CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows in Pharma and Biotech companies.

New Fully Automated Single-Cell Dispenser for Microorganisms

B.SIGHTTM will reduce timelines and cut costs on single-cell microbiology research

| 1 min read
Share this Article
Register for free to listen to this article
Listen with Speechify
0:00
1:00

CYTENA, a BICO group company (Nasdaq Stockholm: BICO), a leading provider of high-precision instruments for handling biological cells, has launched a new instrument to streamline single-cell isolation in microbiology research. The next generation B.SIGHT is taking the company’s automated single-cell isolation capabilities to the next level with special emphasis on handling bacteria, yeast, and other microorganisms.

“The new B.SIGHT brings isolation of bacteria & yeast to the next level” said Dr. Julian Riba, CEO of CYTENA. “This second generation single-cell dispenser is really the outcome of a great collaboration between our team and our customers.”

Lab manager academy logo

Get training in Lab Crisis Preparation and earn CEUs.

One of over 25 IACET-accredited courses in the Academy.

Certification logo

Lab Crisis Preparation course

For years, microbiologists have been interested in fully automating single-cell isolation from complex sample suspension in order to characterize unknown species. The new B.SIGHT has been designed to tackle this challenge efficiently and reliably. “The new instrument provides more automation, faster processing speeds, higher resolution, and precise dispensing,” said Dr. Hussein Hamzeh, the B.SIGHT’s Product Manager. Hamzeh also explained that, in addition to optimizing workflows, the B.SIGHT follows CYTENA’s philosophy on customer-conscious product design. “Researchers using the B.SIGHT not only will be able to accelerate microorganism isolation workflows but also significantly reduce plastic waste.”

CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows in Pharma and Biotech companies. It will also revolutionize the microbiome field by enabling scientists to streamline their microbiome work and accelerate their path towards transformative medicine. “We’re confident we can grow together with the customers who will introduce the B.SIGHT to their lab.” said Riba.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - December 2024

2025 Industry and Equipment Trends

Purchasing trends survey results

Lab Manager December 2024 Cover Image
Lab Manager eNewsletter

Stay Connected

Click below to subscribe to Lab Manager Monitor eNewsletter!

Subscribe Today